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Metabolic effects of FGF-21: 
thermoregulation and beyond
Bin Ni , Jared S. Farrar , Janina A. Vaitkus and Francesco S. Celi*
Division of Endocrinology and Metabolism, Department of Internal Medicine, Virginia Commonwealth University School of 
Medicine, Richmond, VA, USA
Fibroblast growth factor (FGF)-21, a member of the FGF family, is a novel hormone 
involved in the control of metabolism by modulating glucose homeostasis, insulin 
sensitivity, ketogenesis, and promoting adipose tissue “browning.” Recent studies 
demonstrated that brown adipose tissue is not only a target for FGF-21, but is also a 
potentially important source of systemic FGF-21. These findings support the hypothesis 
that FGF-21 plays a physiologic role in thermogenesis and thermogenic recruitment of 
white adipose tissue by an autocrine–paracrine axis. This review examines the role of 
FGF-21 in thermogenesis from the perspective of cell-based, animal model, and human 
studies. We also present recent advances in the characterization of FGF-21’s regulation 
of metabolism.
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introduction
Fibroblast growth factors (FGFs) are a large family of polypeptide growth factors comprised of 22 
different members, with molecular masses ranging from 17 to 34 kDa sharing 13–71% amino acid 
identity. Among vertebrate species, FGFs are highly conserved in both gene structure and amino acid 
sequence (1). FGF-21 is a novel member of the FGF family and is predominantly expressed in the 
liver (2). FGF-21 activity depends on the membrane protein beta-klotho, a co-receptor with a very 
short cytoplasmic domain. FGF-21 binds beta-klotho with its C-terminus and directly interacts with 
FGF receptors (FGFRs) through its N-terminus, resulting in FGFR activation (3). During the past 
decade, FGF-21 has been shown to be a novel regulator of metabolism and a potential therapeutic 
target for the treatment of obesity and diabetes (4).
Adipose tissue is one of the main targets of FGF-21 action, and mammals have at least two differ-
ent types of fat: white and brown. White adipose tissue (WAT) is the primary site of energy storage 
and of release of hormones and cytokines that modulate whole-body metabolism and insulin resist-
ance (5, 6). Brown adipose tissue (BAT) is not only an important body defense against hypothermia 
but also plays a role in diet-induced thermogenesis (7). This energy expenditure is in the form of 
thermogenesis, and is mediated by the expression of uncoupling protein 1 (UCP1). Hence, BAT 
can regulate whole-body metabolism and may alter insulin sensitivity and modify susceptibility to 
weight gain (8, 9).
FGF-21-induced Thermogenesis in Mice
The first study of FGF-21’s function on mouse core body temperature was performed in 2005 by 
Kharitonenkov and colleagues (4). Transgenic mice expressing human FGF-21 under the control 
of an APOE promoter and wild-type littermates were fed a high-fat/high-carbohydrate diet for 
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15 weeks. FGF-21 transgenic mice were resistant to high-fat diet-
induced obesity and their BAT was denser. At room temperature, 
FGF-21 transgenic mice had significantly lower body weight, 
fasting glucose levels and leptin levels, despite a much higher 
food intake compared to wild-type littermates. These data sug-
gest that in a fed state, FGF-21 probably stimulates EE partially 
through increased BAT activation, which in turn results in an 
improved metabolism.
A study on the role of the peroxisome proliferator-activated 
receptor alpha (PPAR-alpha)/FGF-21 endocrine signaling 
pathway found that FGF-21 could reduce physical activity and 
promote torpor, a short-term hibernation-like state of regulated 
hypothermia that conserves energy (10). This was due to direct 
FGF-21 induction by PPAR-alpha in response to fasting, and phar-
macologically by PPAR-alpha agonists. FGF-21, in turn, stimu-
lated lipolysis in WAT and ketogenesis in the liver. In contrast to 
the previous study by Kharitonenkov and colleagues (4), the body 
temperatures of FGF-21 transgenic mice in this study were 1–2°C 
lower than their wild-type littermates. To examine whether core 
body temperature was also affected under conditions in which 
endogenous FGF-21 was increased, wild-type mice were infected 
with an FGF-21 expressing adenovirus. Administration of FGF-
21 resulted in reductions in both basal and fasting-induced body 
temperature. In addition to the reduced core body temperature, 
locomotor activity was also dramatically reduced in FGF-21 
transgenic mice. These data suggest that during fasting states, 
FGF-21 may alter behavior to conserve energy.
Coskun et al. investigated the role of FGF-21 in obese mice 
(11). Systemic administration of FGF-21 for 2  weeks in diet-
induced obese mice and ob/ob mice lowered body weight by 
20%, predominantly via a reduction in adiposity. In this study, 
FGF-21-treated animals exhibited increased EE, fat utilization, 
and lipid excretion, reduced hepatosteatosis, and ameliorated 
hyperglycemia. In contrast to previous studies, no decrease in 
total caloric intake or an effect on physical activity levels were 
observed. After continuous infusion with FGF-21 (1 mg/kg/day) 
for 5  days, a small but significant elevation of core body tem-
perature was observed 4  h after initiation of treatment, lasting 
for approximately 10 h. FGF-21 also increased EE during both 
light and dark cycles, and depressed the respiratory quotient 
(RQ) in the dark cycles. The results of this study contrasts with 
an earlier report (10) where a reduction in body temperature was 
observed. It is important to note that in the former study, obese 
animals with ad libitum access to food were used and the body 
temperatures were measured in the fed state. Lower core body 
temperatures were only observed in lean, starved, and therefore 
energy-deprived FGF-21 transgenic mice and no such effects 
were reported in fed animals. Collectively, the data indicate a 
divergent effect of FGF-21 on core temperature, driven by the 
fed/fasting state.
Subsequently, Hondares and colleagues investigated the 
thermogenic effect of FGF-21 on newborn mice (12). This 
manuscript for the first time provided evidence suggesting that 
a metabolic regulator hormone, produced by the liver, could 
directly mediate activation of brown fat thermogenesis during 
the fetal-to-neonatal transition. The authors found low levels 
of FGF-21 in the plasma of fetal mice. After birth, however, 
plasma FGF-21 levels increased rapidly and remained high for 
6 days before declining. Once weaning had completed, FGF-
21 levels were similar to adult mice. Similarly, Fgf21 mRNA 
levels in both fetal and newborn mouse liver were low. Soon 
after birth, Fgf21 was induced rapidly in the liver, with plasma 
FGF-21 levels reaching that of adults within 16  h. To assess 
whether activation of PPAR-alpha could mediate the action of 
milk lipids on the Fgf21 gene, the authors studied PPAR-alpha 
null pups. Expression of Fgf21 at birth in the liver of PPAR-
alpha null mice was lower than their wild-type littermates. 
Moreover, postnatal induction of the Fgf21 gene mediated 
by milk intake was completely suppressed in PPAR-alpha 
null pups. In wild-type pups starved after birth, injection of 
the PPAR-alpha agonist, pirinixic acid (Wy14,643) induced 
a significant increase in Fgf21 expression levels in the liver, 
whereas no such response was achieved in PPAR-alpha null 
pups. These results, consistent with previous observations (10), 
indicate that PPAR-alpha is necessary for Fgf21 induction in 
a fasting state.
Conversely, Hondares et  al. (12) also found that FGF-21 
could cause thermogenic activation of BAT in newborn mice 
and cultured brown adipocytes. The expression of thermogenic 
activation-related genes was increased in neonatal BAT after 
birth, in parallel with the rise in plasma FGF-21 levels. This study 
also treated neonate pups with a single dose of recombinant 
mouse FGF-21 4 h after birth, without further suckling. A small, 
but statistically significant reduction of blood glucose in the 
absence of differences in free fatty acids or β-hydroxybutyrate 
levels was observed. FGF-21 significantly induced the expres-
sion of genes encoding proteins involved in mitochondrial 
oxidation and BAT thermogenic activation, such as Pgc-1α, 
Ucp1, Dio2, Cyt c, Lipe, Glut1, and Glut4. Additionally, FGF-21 
also increased the protein levels of peroxisome proliferator-
activated receptor γ, coactivator 1α (PGC-1α), UCP1, and 
Cytochrome c. Moreover, PPAR-alpha null pups exhibited a 
reduced postnatal induction of thermogenic genes, which was 
rescued with FGF-21 treatment immediately after birth. Taken 
together, these results (12) confirm the role of PPAR-alpha in 
Fgf-21 induction and FGF-21 activation of BAT thermogenesis 
in neonatal mice.
To assess whether FGF-21 may act directly on BAT, mouse 
brown adipocytes were differentiated in culture and were then 
exposed to FGF-21. At 5  nM, FGF-21 significantly induced 
the expression of genes involved in thermogenic activation 
(Pgc-1α, Ucp1, Glut4, Cyt c), while a higher concentration of 
FGF-21 (50 nM) did not further enhance these effects. Finally, 
mitochondrial function assays demonstrated that FGF-21 caused 
a significant increase in brown adipocyte oxygen consumption. 
FGF-21 treatment increased oligomycin-resistant uncoupled 
phosphorylation, and resulted in a significant induction (roughly 
threefold) of glucose oxidation in brown adipocytes. Additionally, 
these data indicated that FGF-21 specifically targets BAT ther-
mogenic activation and that in neonates, this may contribute to 
neonatal activation of BAT thermogenesis in response to the start 
of milk intake. Collectively, these studies in mice demonstrate 
that FGF-21 is an important regulator of metabolism during 
fasting and fed states.
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Direct Release of FGF-21 by Brown 
Adipose Tissue
Although the liver is a well-known site for FGF-21 generation 
(2), Hondares et al. studied whether thermogenic activation in 
adult mice could directly induce FGF-21 expression and release 
in BAT (13). In this study, adult male mice were exposed to a 4°C 
housing environment for 6 or 24 h. This cold exposure caused a 
remarkable increase (40-fold) in Fgf21 expression levels in BAT. 
Chronic acclimation to 4°C over 30 days also resulted in a signifi-
cant induction of Fgf21 expression. In contrast, Fgf21 expression 
levels were not significantly increased in the livers of mice acutely 
exposed to cold and were even reduced in mice acclimated to 
cold during a 30-day exposure. In mice exposed to cold for 24 h, 
a modest increase in Fgf21 mRNA was observed in WAT. Thus, 
whereas Fgf21 mRNA levels in BAT at thermoneutrality were 
lower than in the liver and WAT, after thermogenic activation, 
BAT showed the highest levels of Fgf21 mRNA expression. 
Plasma levels of FGF-21 in mice did not change after 6 h, but 
increased after 24 h of cold exposure, and increased even further 
after a 30-day cold acclimation period. The authors also found 
that there were significant negative arteriovenous gradients in 
FGF-21 concentration across interscapular BAT from rats after 
short term (24 h) cold exposure and long term (30 day) accli-
mation to cold exposure, demonstrating a significant FGF-21 
output from BAT. Very recently, Keipert and colleagues showed 
that in UCP-1 knockout mice, cold exposure induces a dramatic 
increase in FGF-21 serum levels and FGF-21 expression in BAT 
compared to wild-type controls (14). This experimental model 
of ablation of non-shivering thermogenesis (NST) provided 
compelling evidence that FGF-21 acts in an autocrine–paracrine 
fashion on BAT, contributing to the adaptive thermogenic 
response and browning of WAT, ultimately expanding the NST 
capacity.
Molecular Mechanisms of FGF-21-induced 
Thermogenesis
The mechanisms which mediate the induction of Fgf21 gene 
expression in response to cold were also investigated by Hondares 
et  al. (13). Norepinephrine, a main mediator of cold-induced 
thermogenic activation of BAT, significantly induced Fgf21 
expression in cultured, differentiated mouse brown adipocytes. 
The same response was observed in brown adipocytes treated 
with cyclic adenosine monophosphate (cAMP). The induction 
of Fgf21 gene expression by either norepinephrine or cAMP in 
brown adipocytes led to a significant increase in the release of 
FGF-21 into the cell culture medium. Treatment of brown adi-
pocytes with propranolol, a β-adrenergic antagonist, successfully 
suppressed the effects of norepinephrine on Fgf21 gene expres-
sion, whereas prazosin, an α-adrenergic inhibitor, had no effect. 
Furthermore, treatment with a protein kinase A (PKA) inhibitor 
(H89) or p38 mitogen-activated protein kinase (MAPK) inhibitor 
(SB202190) suppressed the induction of Fgf21 gene expression by 
norepinephrine. These results indicate that norepinephrine acts 
through β-adrenergic receptors to increase cAMP levels, causing 
cAMP-mediated activation of PKA and p38 MAPK pathways and 
induction of Fgf21 gene expression.
The authors also used HIB-1B cells [a brown adipocyte cell line 
derived from a transgenic mouse brown fat tumor (15)] to further 
investigate how Fgf21 gene transcription was regulated. HIB-1B 
cells were co-transfected with a luciferase reporter construct with 
a Fgf21 gene promoter and active form of PKA. By treating with 
dibutyryl cAMP, a significant increase in Fgf21 promoter activity 
was found. Furthermore, both active (MKK6-Glu) and inactive 
(MKK6-K82A) forms of the upstream inducer of p38 MAPK, 
MKK6, were tested for their role in Fgf21 promoter activity. Only 
MKK6-Glu could significantly induce Fgf21 promoter activity 
after transfection in the cell, which indicated that PKA-mediated 
activation of Fgf21 transcription is p38 MAPK dependent. 
Additionally, in a chromatin immunoprecipitation experiment, a 
very strong binding of ATF2 (cyclic AMP-dependent transcrip-
tion factor) to the Fgf21 promoter was observed, suggesting that 
cAMP can promote this binding event in brown adipocytes. These 
data provide a link between sympathetic activation during cold 
stress and the release of FGF-21 from brown adipocytes. Finally, 
this study also demonstrates that ATF2 binding to the Fgf21 gene 
promoter is essential for cAMP-dependent induction of Fgf21 
gene transcription. Further studies investigating the binding of 
ATF2 to the Fgf21 promoter may reveal novel regulators and the 
role of histone remodeling in Fgf21 induction.
FGF-21 Function in Human Brown  
Adipose Tissue
In 2013, our lab first discovered the effects of mild cold exposure 
on circulating FGF-21 levels in healthy humans and its relation-
ship with cold-induced thermogenesis and lipolysis (16). Twelve 
healthy volunteers were included in a randomized, single-blind, 
crossover intervention study. All subjects were exposed to 24 and 
19°C in a whole-room indirect calorimeter for 12 h. EE, plasma 
FGF-21, non-esterified fatty acid (NEFA), and adipose tissue 
glycerol concentrations were measured. First, we found that plasma 
FGF-21 exhibited a two- to threefold diurnal variation at 24°C, 
peaking at 0800  hours and progressively dropping to a nadir at 
1700 hours, before rising at 1900 hours. We next compared in the 
same volunteers FGF-21 levels in blood samples obtained at 24°C 
and at 19°C. The diurnal rhythm of plasma FGF-21 concentration 
was retained at 19°C; however, the rise in FGF-21 levels in the late 
afternoon observed at 24°C was not. Plasma FGF-21 concentration 
was significantly higher at 19°C compared with 24°C at paired time 
points of cold exposure. Compared with 24°C, at 19°C the FGF-21 
area-under-the-curve (AUC) was significantly increased. Also, the 
change in adipose tissue microdialysate glycerol concentrations 
between 19 and 24°C correlated positively with the change in 
plasma FGF-21 levels, but not the change in serum NEFA AUC. 
Total energy expenditure (TEE, or EE) was significantly higher 
at 19°C compared with 24°C, and the change in plasma FGF-21 
concentration correlated positively with the change in EE. In a 
multivariate analysis, the change in plasma FGF-21 concentrations 
predicted the change in TEE. Collectively, our study demonstrated 
that mild cold exposure elevates circulating FGF-21 levels in 
humans. Augmented FGF-21 levels correlated positively with 
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increments of adipose tissue microdialyzate glycerol and TEE 
during cold exposure. To our knowledge, this was the first study 
revealing potential regulatory links between FGF-21, lipolysis, and 
cold-induced thermogenesis in humans.
More recently, we explored cold exposure-induced FGF-21 
secretion in humans and compared it with FNDC5 (also termed 
Irisin) (17). To elucidate whether BAT is a significant source of 
cold-augmented FGF-21 secretion, we profiled FGF-21 levels in 
five healthy men, stratified by BAT status, during 5 h of either a 
mildly cold non-shivering condition (19°C) or thermoneutrality 
(24°C). Consistent with our previous findings, diurnal reduction 
of FGF-21 was blunted at 19°C. However, the blunting effect was 
markedly greater in BAT-positive subjects compared to BAT-
negative subjects, translating to a total FGF-21 output more than 
sixfold higher in BAT-positive individuals. Since the subjects 
were of similar age and body composition, and differed only by 
BAT status, these associative results support BAT as a source 
of FGF-21 during cold exposure in humans. Interestingly, the 
biorhythm of FGF-21 was virtually identical when subjects were 
exposed to warm temperature (27°C), and we observed a trend 
between FGF-21 diurnal reduction and shivering intensity (17).
We next examined the bioenergetic profiles of FGF-21-treated 
primary human adipocytes in  vitro, which were established 
from deep neck fat biopsies, a location known to be enriched 
with beige adipocytes (18). FGF-21 treatment increased general 
BAT and beige gene expression, without altering expression 
levels of classic brown fat lineage genes. UCP1 protein, which 
was absent in untreated adipocytes, became strongly expressed 
following FGF-21 treatment. During an adipocyte thermogenic 
function assay, FGF-21 significantly enhanced adipocyte basal 
oxygen consumption rate measured with an extracellular fluid 
bioanalyzer. Pharmacological interrogation of mitochondrial 
respiration revealed augmentation of both forms of respiratory 
uncoupling (oligomycin resistant and maximal) by FGF-21 treat-
ment. Since the primary function of BAT is the generation of heat, 
we quantified the heat production from adipocytes directly by 
infrared thermography. FGF-21 increased heat production only 
after norepinephrine exposure. Thus, not only norepinephrine is 
required for FGF-21 induction and release in BAT (13), it is also 
required for FGF-21-induced thermogenesis in BAT. In contrast, 
FNDC5 treatment enhanced adipocyte heat production dose 
dependently, and was further increased by norepinephrine (17).
Most recently, serum FGF-21 levels were correlated with BAT 
activity in humans (19). A total of 59 lean and healthy subjects were 
included in two different cooling protocols: air-cooling (20, 21) 
and water-perfused suit (22, 23), followed by a [18F]FDG-PET/CT 
scan as a measure for BAT activity. In agreement with our previous 
study, serum FGF-21 levels were positively correlated with human 
cold-induced BAT activity. Interestingly, this was observed only in 
men, although BAT is more likely to be detected in females than 
in males (24). In contrast to our previous studies, the authors did 
not find an effect of acute cold exposure on plasma FGF-21 levels, 
but did observe an increase after a 10-day cold acclimation period, 
in parallel with upregulation of BAT activity. These results further 
support a role for FGF-21 as a cold-induced activator and product 
of BAT. Additionally, basal FGF-21 levels correlated positively with 
the change in core body temperature upon cold exposure for both 
males and females in both the water-cooling group and the air-
cooling group. This result suggests that in humans, FGF-21 may 
play a novel role in maintaining core body temperature in response 
to reduced ambient temperature.
Metabolic Benefits of an FGF-21 Analog
In a clinical setting, elevated serum FGF-21 levels have been observed 
in obese, glucose intolerant, and diabetic patients (25–27). FGF-21 
levels are positively correlated with adiposity, plasma glucose, and 
insulin levels (indices of insulin resistance and triglyceride (TG) 
levels), and negatively correlated with high-density lipoprotein 
cholesterol (HDL-C) (28). So far, no data are available on direct 
administration of native FGF-21 to humans; however, a FGF-21 
analog (LY2405319) has shown promise in obese human subjects 
with type 2 diabetes (29, 30). LY2405319 is a biopharmaceutical 
optimization of native FGF-21 with enhanced physical stability, and 
is able to maintain biological potency in vivo more successfully than 
the native molecule (31). During a clinical study, LY2405319 (3, 10, 
20 mg/kg/day) was injected subcutaneously for 28 days. Compared 
with placebo, the 10 and 20 mg groups showed reductions in low-
density lipoprotein cholesterol (LDL-C) by 29.5 and 20.2%, respec-
tively. An additional significant decrease in mean fasting TG levels 
appeared as early as day 2 for all three dosing groups. The reduction 
in fasting TG levels was maintained for the entire treatment period 
and was significantly different from baseline and placebo at the 10 
and 20 mg dosage levels. Total cholesterol concentrations were also 
lowered in the 10 (−19.2%) and 20  mg/kg/day (−15.4%) groups. 
Additionally, an increase of 15–20% in HDL-C occurred across all 
three dosage groups. Compared with baseline, both 10 and 20 mg 
dosage groups had a significant decrease in body weight (−1.75 and 
−1.49 kg). There was a trend of lower glucose levels in all dosage 
groups, and fasting insulin levels were significantly reduced in the 
20  mg dose group when compared to baseline. In mice, FGF-21 
administration lowered body weight and increased metabolic rate 
without suppressing food intake (11). In the human clinical study, 
neither caloric intake nor EE were measured. However, the sig-
nificant increase in β-hydroxybutyrate in all LY2405319-treated 
groups suggests that TEE might have been increased, since 
β-hydroxybutyrate has a substantial thermic effect in humans, 
leading to an increase in EE (32). Thus, it would appear that despite 
elevated baseline FGF-21 levels (“FGF-21 resistance”), obese indi-
viduals with type 2 diabetes may still benefit from administration 
of an FGF-21 analog. Future studies are still needed to determine 
the potential metabolic benefits of interventions, which increase 
endogenous FGF-21 levels in this population.
Metabolic Benefits of FGF-21 May Be 
“Browning” independent
Brown adipose tissue has been increasingly recognized as a 
natural target for the modulation of EE. This tissue is very dif-
ferent from a white fat depot, in that it requires the uptake of 
free fatty acids and glucose for activation and expends energy 
instead of storing it (33). Although the most important functions 
of BAT in small mammals are thermogenesis and maintenance 
of core body temperature, more recent evidence has shown that 
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this tissue may represent an important target in humans for the 
treatment of obesity (34–36) and type 2 diabetes (37–39). Due 
to FGF-21’s function as an important thermogenic regulator, its 
role in energy metabolism has also been widely investigated (4, 
11, 40, 41). These in vivo studies used ob/ob, db/db, diet-induced 
obese, and FGF-21 transgenic mice models. FGF-21 transgenic 
mice had significantly lower body weight, fasting glucose levels, 
and hepatic fat deposition. They also retained more BAT, had 
subcutaneous adipocytes of smaller size, and exhibited improved 
glucose clearance and insulin sensitivity when compared to 
control littermates. Pharmacologic administration of FGF-21 
dose dependently (0.1–10 mg/kg/day) reduced body weight and 
whole-body fat mass in diet-induced obese mice by increasing EE 
and physical activity levels. In diet-induced obese mice, FGF-21 
also reduced blood glucose, insulin, and lipid levels, and reversed 
hepatic steatosis. Similarly, FGF-21 administration improved 
hepatic and peripheral insulin sensitivity in both lean and diet-
induced obese mice, independent of a reduction in body weight 
and adiposity. Finally, it is worth noting that exogenous FGF-21 
can promote reductions in fasting glucose levels, body weight, 
and circulating lipid levels in obese diabetic rhesus monkeys (42).
Recently, it has been debated whether the metabolic benefits 
of FGF-21 are “browning” and UCP1 dependent (43–45). These 
articles highlight a common pharmacological role for FGF-21 
independent from BAT, since FGF-21 is effective in UCP1 null 
mice to reduce food intake for the promotion of weight loss. 
The majority of FGF-21-driven metabolic endpoints seem to 
not require UCP1 nor white adipocyte browning (brite or beige 
adipocytes); the browning of WAT by FGF-21 is dependent on 
temperature and diet, and UCP1 is only essential for helping 
FGF-21 regulate EE. These results are not surprising because 
FGF-21 acts through a cell-surface receptor complex composed 
of conventional FGFRs and beta-klotho (3, 46, 47). It is worth 
noting that both beta-klotho and FGFR1 are expressed not only 
in adipose tissue, but also in the liver and pancreas (48–50). Beta-
klotho is also expressed in the suprachiasmatic nucleus (SCN) 
of the hypothalamus and the dorsal vagal complex (DVC) of the 
hindbrain in mice and this expression allows FGF-21 to regulate 
circadian behavior and metabolism at the level of the central 
nervous system (CNS) (51). Interestingly, the same study noted 
that the metabolic effects of FGF-21 overexpression to reduce 
blood glucose and insulin levels required beta-klotho expression 
in the SCN. This suggests that the CNS is pivotal in modulating 
the metabolic actions of FGF-21 in peripheral tissues, such as 
the liver and adipose tissue, and future studies are necessary to 
elucidate these pathways.
Skeletal muscle is also a target tissue for FGF-21 function (45, 
52, 53). Skeletal muscle is strongly dependent on oxidative phos-
phorylation for energy production, and at the same time, skeletal 
muscle insulin resistance in type 2 diabetes and obesity involves 
dysregulation of the oxidation of both carbohydrate and lipid fuels. 
A recent study showed that in skeletal muscle from subjects with 
mitochondrial disorders, there was an increase in FGF21 expression 
likely representing a compensatory mechanism (54). FGF21 was 
induced in the skeletal muscle tissue of patients with mitochondrial 
oxidative phosphorylation deficiency and compensated for the 
metabolic energy deficiency by mammalian target of rapamycin 
(mTOR) activities, which serve as a master regulator of cell metabo-
lism and energy homeostasis (55) via the PI3K–Akt pathway in 
skeletal muscle cells. mTOR can also increase the expression levels 
of YY1 and PGC-1α, resulting in enhanced mitochondrial oxidative 
function. FGF-21-enhanced mitochondrial function was also dem-
onstrated by significant increases in mitochondrial ATP synthesis, 
oxygen consumption rate, glycolytic capacity, activity of citrate 
synthase, and expression of key energy metabolism genes, such as 
Glut1, Cpt1a, Cpt2, Cycs, and Idh3a. All of these regulatory changes 
and recent insights into FGF-21 signaling in the brain contribute to 
the new role of FGF-21 in lipid and glucose metabolism, independ-
ent of thermogenesis or WAT “browning.”
Concluding Remarks and Future 
Perspectives
Fibroblast growth factor-21 is a pleiotropic metabolic regulator 
which can reverse obesity and diabetes in different animal models 
and whose pharmacologic effects can be “browning” or UCP1-
independent. In humans, a FGF-21 analog administration results 
in important metabolic effects, but further studies are required 
to elucidate the exact mechanisms of FGF-21 action. By taking 
advantage of dense phenotyping techniques with quantitative 
functional imaging of BAT, we hope to investigate whether or not 
individuals with greater initial BAT abundance or induced beige 
fat will have differential metabolic benefits during treatment with 
FGF-21 or its analogs (Figure 1).
FiGURe 1 | Hypothetical metabolic benefits of FGF-21 in BAT-positive and 
BAT-negative individuals. Green blocks indicate theoretical baseline metabolic 
benefits without FGF-21 or analog administration. At baseline BAT-positive 
individuals are expected to exhibit greater beneficial metabolic profiles than their 
BAT-negative counterparts. Yellow blocks indicate potential changes to baseline 
metabolic benefits after FGF-21 or analog administration. The presence and 
magnitude of these changes in both BAT-positive and BAT-negative patients have 
yet to be elucidated and are a target of future research.
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